mms mohamad zahreddine

As Chief Information and Technology Officer and a member of the Executive Team at MMS, Mohamad Zahreddine is responsible for overseeing the operational and strategic aspects of the company’s Technologies, Quality and Compliance, Business Process Transformation, Product Development, Information Security, and overall Governance. 

He has established governance over key enterprise business processes and led the formation and implementation of a holistic technology, governance, and compliance strategy. By leading quality and compliance and developing tech-enabled enterprise strategies, Mohamad’s role is integral in developing solutions for both internal and customer processes. He has expertise in global ERP implementations, manufacturing systems and processes, engineering systems, sales and operations, and information security, including technical and quality certifications. He is proficient and experienced at identifying emerging technology needs within the pharmaceutical industry, including regulatory requirements and IT controls to support clinical trial execution and transparency.

In the pharmaceutical industry, technological advancements are constantly evolving to effectively bring life-changing therapies to market. Change should be embraced, not feared, in all levels of business in order to move forward.
Mohamad Zahreddine
Chief Operating Officer

Mohamad brings a visionary approach with nearly 30 years of global experience in Business and Information Technology (IT), Global Enterprise Resource Planning (ERP), and a strong passion for digital transformation. Prior to MMS, he held several global leadership positions in the industry and led multiple IT and business systems transformation initiatives. Mohamad holds a Master of Science in Computer and Information Systems from the University of Detroit Mercy and a Bachelor’s degree in Computer Information Systems from the Detroit College of Business. He is also a member of the Forbes Technology Council.

Suggested For You

perspectives

January 21st, 2025

REMS Modifications and Revisions: A Retrospective from the Past 12 Months

regulatory intelligence

January 17th, 2025

The FDA’s AI Guidance and its Seven Steps into the Future of Drug Development

regulatory intelligence

January 17th, 2025

New FDA Protocol Deviation Guidance:  Planning for the Things That Don’t Go According to Plan

perspectives

January 9th, 2025

How to Create Efficiencies When Creating Simultaneous NDA and MAA Submissions for the FDA and EMA

perspectives

January 2nd, 2025

Informed Consent in Clinical Research: Understanding its Significance and Sponsor Obligations

perspectives

December 17th, 2024

Oncology Drug Development: Webinar Learnings on the Use of Expedited Pathways and Oncology Center of Excellence Programs

perspectives

December 11th, 2024

Why Emerging Biotech Companies are Increasingly Turning to Specialized Data CROs

regulatory intelligence

December 4th, 2024

FDA Issues Detailed Guidance on Development of Gene Therapy Products

news

December 4th, 2024

AI in Pharma and Innovative Leadership Were on Display at the Biennial MMS Scientific Symposium

perspectives

November 26th, 2024

Finding GRASEland: Navigating the New Regulatory Path for Grandfathered OTC Drugs 

perspectives

November 21st, 2024

Essential Nonclinical Strategies for Cell and Gene Therapy (CGT) Success

news

November 19th, 2024

MMS Recognized as a Top Workplace by Detroit Free Press and USA Today Network for the Fourth Consecutive Year